Ardelyx, Inc. (NASDAQ:ARDX)
| Market Cap | $751.60M-45.6% |
| Revenue (ttm) | $468.22M+17.6% |
| Net Income | -$55.47M+1.9% |
| EPS | -$0.22+4.2% |
| Shares Out | 251.37M |
| PE Ratio | n/a |
| Forward PE | 15.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,200,407 |
| Open | $3.03 |
| Previous Close | $3.06 |
| Day's Range | $2.95 - $3.08 |
| 52-Week Range | $2.80 - $8.40 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | $13.00(+334.78%) |
| Earnings Date | Feb 18, 2027 |
About ARDX
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating ARDX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 18, 2027Earnings report
$ARDX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ARDX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ARDX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ARDX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ARDX Revenue by Segment or Geography
| Product sales, net | $125.45M | 98.74% |
| Product supply revenue | $1.38M | 1.09% |
| Licensing revenue | $216.00K | 0.17% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ARDX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ARDX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ARDX
| XBIState Street SPDR S&P Biotech ETF | $22.81M |
| IWMiShares Russell 2000 ETF | $19.33M |
| VTIVanguard Morningstar Total Stock Market ETF | $17.68M |
| PBEInvesco Biotechnology & Genome ETF | $9.65M |
| VXFVanguard Extended Market ETF | $8.57M |
| IWOiShares Russell 2000 Growth ETF | $6.99M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ARDX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| PBE | Invesco Biotechnology & Genome ETF | 2.22% |
| BBP | Virtus Biotech ETF | 0.71% |
| TSCV | Thrivent ETF Trust - Small Cap Value ETF | 0.37% |
| XBI | State Street SPDR S&P Biotech ETF | 0.23% |
| ISMD | Inspire Small/Mid Cap ETF | 0.18% |
| ESSC | Eventide Small Cap ETF | 0.11% |
| FSML | Franklin Small Cap Enhanced ETF | 0.09% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.05% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.05% |
| IWO | iShares Russell 2000 Growth ETF | 0.05% |
| PWS | Pacer WealthShield ETF | 0.04% |
| LABU | Direxion Daily S&P Biotech Bull 3X Shares | 0.04% |
Weight is the stock’s share of each fund’s holdings.
